|
|
||||||||


*
Biomedical Research Center, Osaka University Medical School, Yamada-oka, Suita, Osaka, Japan; Departments of
Bacteriology and
Immunology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; and
§
Fujisaki Institute, Hayashibara Biochemical Laboratories, Okayama, Japan
| Abstract |
|---|
|
|
|---|
-inducing factor/IL-18 has been shown to
stimulate T cells for IFN-
production and growth promotion.
Considering the NK-stimulatory capacity of IL-12, we investigated the
effect of IL-18 on NK lineage cells. A
CD4-CD8-surface
Ig-Ia- fraction of freshly prepared C57BL/6
spleen cells proliferated strikingly in response to combinations of
IL-12 + IL-18 or IL-2 + IL-18, but not to the individual
cytokines or IL-2 + IL-12. Cells proliferating in response to
IL-2 + IL-18 were NK1.1+CD3-, whereas
IL-12 + IL-18-responsive cells were
NK1.1-CD3-. Restimulation of the former cells
with IL-12 + IL-18 or the latter cells with IL-2 + IL-18
resulted in the generation of NK1.1-CD3- or
NK1.1+CD3- cells, respectively. Moreover, a
NK1.1+CD3-CD4-CD8-surface
Ig-Ia- population isolated from spleen cells
was found to form NK1.1+CD3- or
NK1.1-CD3- blasts by stimulation with
IL-2 + IL-18 or IL-12 + IL-18, respectively, and the NK1.1
positivity on these blasts was again reversed after restimulation with
an alternative combined stimulus. Both types of blasts produced
enormously large amounts of IFN-
in response to IL-12 + IL-18
and exhibited strikingly high levels of NK activity. These results
indicate that IL-18 plays an obligatory role in inducing proliferation
and activation of
NK1.1+CD3-CD4-CD8-
cells and that the expression of the NK1.1 marker is reversible,
depending on the cytokine used for stimulation in combination with
IL-18. | Introduction |
|---|
|
|
|---|
after microbial infection or to exhibit
cytotoxicity against infected cells, before the clonal expansion and
differentiation of Ag-specific T cells, is important in the innate
immune response (3, 4).
Most facets of NK cell biology have been the expression of
cytotoxicity, cytokine secretion, and IL-2-induced expansion (5). For
example, NK cells exhibit enhanced cytolysis, IFN-
secretion, and
proliferative activity in response to IL-2 and represent the
predominant IL-2-induced lymphokine-activated killer cell activity
(6, 7, 8). However, in the last several years, additional cytokines have
been found to dramatically regulate NK cell activity in vitro and in
vivo. In particular, IL-12 has been shown to be a potent stimulator of
mature NK and T cells (9, 10, 11, 12, 13, 14, 15, 16). The effects of this cytokine on both
lineages of cells include: 1) production of IFN-
and other cytokines
(10, 13) requiring participation of accessory cells (13); 2)
enhancement of cytotoxicity induced directly by IL-12 (14); and 3)
proliferation of previously activated cells (15, 16). Thus, unlike
IL-2, IL-12 induces little or no proliferation in resting NK and T
cells. Moreover, IL-12 requires the presence of accessory cells for the
stimulation of IFN-
production. This may be consistent with the fact
that IL-1ß is required for IL-12 to induce IFN-
production by NK
cells (17). While IL-2 is a cytokine produced by activated T cells in
an acquired immune response, little is known regarding how NK cell
growth is supported in the innate immune response before T
cell-mediated protective immunity develops. It also remains to be
investigated whether additional cytokine(s) regulates the function of
NK cells, alone or in combination.
Recently, another proinflammatory cytokine with the ability to markedly
stimulate IFN-
production by T cells and NK cells was discovered and
designated IFN-
-inducing factor (18), now termed IL-18. Our previous
study showed a striking synergy between IL-12 and IFN-
-inducing
factor/IL-18 in enhanced production of IFN-
by a cloned T cell
line (19). The present study investigated the effect of IL-18 on the
proliferation and activation of NK cells. The results show that IL-18,
in combination with either IL-12 or IL-2, induced much higher levels of
proliferation of
NK1.1+CD3-CD4-CD8-
cells than did IL-2 or IL-12 alone, or the combination of IL-2 plus
IL-12. Moreover, NK cells activated with either IL-12 + IL-18 or
IL-2 + IL-18 expressed the capacity for strikingly high levels of
IFN-
secretion and exhibited potent cytotoxicity against various
tumor cells. Such an enhanced NK activity was not induced by either the
combination of IL-12 or IL-2 with various other cytokines including
IL-1ß or by various combinations of cytokines excluding IL-18. Thus,
these results indicate an obligatory role for IL-18 in mediating the
growth promotion and enhanced function of NK cells.
| Materials and Methods |
|---|
|
|
|---|
C57BL/6 (B6) mice and B6 (nu/nu) mice were purchased from Shizuoka Laboratory Animal Center, Hamamatsu, Japan, and CLEA JAPAN, Kanagawa, Japan, respectively. Animals were used at 6 to 7 wk of age.
Reagents
The following recombinant mouse cytokines were obtained: rIL-12
and rIL-18 (previously described as IFN-
-inducing factor) were
expressed and purified at Hayashibara Biochemical Laboratories as
previously described (20, 21); rIL-2 was kindly provided by Shionogi
Research Laboratories, Osaka, Japan; rIL-1ß was purchased from
Genzyme, Cambridge, MA.
The following mAbs or polyclonal Ab were used:
anti-I-Ad/b (34-5-3S) (22) and anti-CD16/32
(Fc
R III/II) (23) were prepared from the culture supernatants of the
relevant hybridoma cells; and anti-CD4 (ATCC clone GK1.5),
anti-CD8 (ATCC clone 2.43), and anti-IL-2R
-chain (7D4) (24)
were prepared from the ascitic fluid of the relevant hybridoma cells
and purified in our laboratory; phycoerythrin
(PE)3-conjugated
anti-CD4, FITC-conjugated anti-CD8, FITC-conjugated
anti-CD4, PE-conjugated anti-B220, FITC-conjugated
anti-CD5, PE-conjugated anti-NK1.1, FITC-conjugated
anti-Mac-1, FITC-conjugated anti-CD3
, FITC-conjugated
anti-Thy-1.2, and biotinylated anti-Sca-1 mAbs were purchased
from PharMingen, San Diego, CA; anti-IL-2R
-chain mAb was
biotinylated in our laboratory; rabbit anti-mouse
asialo-GM1 Ab was from Wako Pure Chemicals, Osaka, Japan;
biotinylated goat anti-rabbit IgG (Wako Pure Chemicals),
biotinylated mouse anti-rat IgG (Jackson ImmunoResearch, West
Grove, PA), PE-conjugated streptavidin (Becton Dickinson, San Jose,
CA), and RED670-conjugated streptavidin (Life Technologies,
Gaithersburg, MD) were also purchased.
Preparation of lymphoid populations
Negative selection. Spleen cells were depleted of CD4/CD8 T cells, B cells, and Ia+ APCs by immunomagnetic negative selection as described (25). Briefly, Ia+ APC in a splenic cell population were allowed to react with anti-I-Ad/b mAb. Spleen cells containing these labeled cells and surface Ig+ (sIg+) cells (B cells) were incubated with magnetic particles conjugated to goat anti-mouse IgG (Advanced Magnetic, Cambridge, MA). sIg- and Ia- cells (B cell- and APC-depleted population) were obtained by removing cell-bound magnetic particles with a rare earth magnet (Advanced Magnetic). CD4+ and CD8+ T cells were depleted by incubation with anti-CD4 and anti-CD8 mAb followed by magnetic particles conjugated to goat anti-rat IgG (Advanced Magnetic).
Positive selection.
CD3-NK1.1+ and
CD3-NK1.1- cells were sorted from the above
CD4-CD8-sIg-Ia-
splenic population by EPICS Elite (Coulter, Miami, FL). Briefly, cells
were incubated with PE-conjugated anti-NK1.1 and FITC-conjugated
anti-CD3
, and the stained cells were sorted into
CD3-NK1.1+ and
CD3-NK1.1- populations. The purities of these
populations were >96 and 94%, respectively.
Cell cultures
Splenic cell populations were cultured with various combinations of cytokines in 96-well flat-bottom microculture plates (Corning 25860, Corning Glass Works, Corning, NY) or in 24-well culture plates (Corning 25820). For determination of [3H]TdR uptake, cells were cultured in 0.2 ml of RPMI 1640 medium supplemented with 10% fetal bovine serum and 2-ME at 4.0 x 104 (fresh spleen cells) or 1.0 x 104 (blasts harvested from primary cultures) cells/well of 96-well microculture plates in a humidified atmosphere at 5% CO2 at 37°C for various days. The cultures were conducted in triplicate and harvested after an 8-h pulse with 20 kBq/well [3H]TdR. Results were calculated from uptake of [3H]TdR and expressed as the mean cpm ± SD of triplicate cultures. For assays other than [3H]TdR incorporation, cells were cultured in 24-well culture plates in a volume of 2 ml at 2.5 x 105 (fresh spleen cells) or 1.0 x 105 (blasts harvested from primary cultures) cells/well. Culture supernatants (SNs) and cells were harvested after various days in culture.
Measurement of IFN-
concentration
IFN-
concentration was measured by ELISA as described (19):
mouse IFN-
ELISA kits were purchased from Genzyme; and our own ELISA
system was prepared using two types of anti-mouse IFN-
mAbs
(XMG1.2 (Endogen, Cambridge, MA)) and biotinylated R4-6A2 (R4-6A2 was
purified from R4-6A2 hybridoma and biotinylated in our laboratory)) as
well as mouse rIFN-
provided from Shionogi, Osaka, Japan. One
unit/ml of IFN-
in our ELISA system corresponded to
100 pg/ml in
Genzyme ELISA kits.
Cytotoxicity assays
Target cells were 51Cr labeled and incubated with various effector populations for 4 h. Percent specific lysis was calculated as previously described (26). SE of the means were excluded from the figures, because they were consistently <5%.
Immunofluorescence and flow cytometry
Cells were first incubated with anti-CD16/32 (Fc
R III/II)
mAb and normal mouse serum to prevent the binding of staining mAbs with
FcRs. These treated cells were then stained directly with FITC- or
PE-conjugated reagents or sequentially with biotinylated mAb followed
by PE- or RED670-conjugated streptavidin. Stained cells were analyzed
with a FACSCalibur (Becton Dickinson, Mountain View, CA).
| Results |
|---|
|
|
|---|
IL-12 and IL-18 both have the capacity to stimulate both T and NK
lineages of cells (9, 10, 11, 12, 13, 14, 15, 16, 18, 19, 20). We first examined whether these
cytokines, alone or in combination, can induce proliferation of a
splenic population obtained following elimination of
sIg+ and Ia+ cells (B cells and APC) from
B6 spleen cells (Fig. 1
A,
left). Neither cytokine alone elicited
[3H]TdR uptake by a B cell/APC-depleted splenic
population during the entire culture period. However, simultaneous
stimulation with IL-12 and IL-18 resulted in a striking proliferative
response. To examine whether T cells are the responders to IL-12 +
IL-18 stimulation, B cell + APC-depleted spleen cells from B6
athymic mice were stimulated with either cytokine or their combination
(Fig. 1
A, right). These spleen cells also
exhibited marked proliferation when stimulated with the two cytokines.
Proliferating cells harvested from the above two cultures were stained
doubly for CD4 and CD8. Lower panels of Figure 1
show that almost all
proliferating cells from athymic mouse spleen cells are
CD4-CD8- (double negative (DN)) and DN cells
are also the predominant blasts in cultures of B cell/APC-depleted B6
splenic populations. These results suggest that a splenic population
depleted of CD4/CD8 T cells, B cells, and Ia+ APC responds
directly to a combination of IL-12 + IL-18 with striking levels of
proliferation.
|
B6 spleen cells were depleted of CD4+ and
CD8+ T cells together with B cells and APC. As shown in
Figure 2
, the resultant population
designated
CD4-CD8-sIg-Ia-
consisted of NK1.1+CD3-,
NK1.1-CD3-,
NK1.1+CD3+, and
NK1.1-CD3+ subsets. This
CD4-CD8-sIg-Ia-
population was stimulated with various cytokines, alone or in
combination (Fig. 3
). The results show
that stimulation with IL-12 + IL-18 again induced marked levels of
proliferation, and comparable levels of proliferation were elicited
when IL-18 was combined with IL-2 instead of IL-12. The doses of IL-12,
IL-2, and IL-18 required to induce synergistic proliferation were
titrated. These cytokines exerted their effects in the ranges of 1 to
1000 pg/ml for IL-12, 1 to 100 U/ml for IL-2, and 1 to 1000 ng/ml for
IL-18, and their optimal doses were found to be 250 to 500 pg/ml
(IL-12), 20 to 100 U/ml (IL-2), and 10 to 100 ng/ml (IL-18). Under the
culture conditions used here (2.5 x 105 cells/well in
24-well culture plates or 4 x 104 cells/well in
96-well microplates), individual cytokines including IL-2 failed to
generate sufficient numbers of blasts and to induce
[3H]TdR uptake (data not shown). When IL-2 was combined
with IL-12, significant levels of proliferation were detected at later
time points (8 or 9 days after culture) (Fig. 3
). However, such
proliferative responses were much weaker compared with those induced by
cytokine combinations involving IL-18. Considering the structural
similarity between IL-18 and IL-1
or IL-1ß, the stimulatory
capacity of IL-12 + IL-1
or ß or IL-2 + IL-1
or
IL-1ß was also examined. IL-1
or IL-1ß could not induce
detectable levels of proliferation even when combined with IL-12 and
IL-2 (data not shown). Thus, these results indicate that IL-18 plays an
obligatory role in inducing high levels of proliferation of a
CD4-CD8-sIg-Ia-
splenic population in collaboration with either IL-12 or IL-2.
|
|
R lIl/ll (CD16/32) was detected only on IL-2 + IL-18
blasts in parallel to the NK1.1 positivity. Thy-1.2 and
asialo-GM1 as well as lymphoid activation markers (Sca-1
and B220) were observed on both types of blasts, whereas both were
negative for T cell markers including CD3, CD4, CD8, and CD5. Thus,
stimulation with IL-12 + IL-18 or IL-2 + IL-18 generates
phenotypically distinct blasts regarding the expression of NK
markers.
|
We investigated whether or not NK1.1+ and
NK1.1- blasts generated by stimulation with different
combinations of cytokines represent two subsets that have
differentiated into mutually independent lineages of cells (Fig. 5
). A
CD4-CD8-sIg-Ia-
population was cultured in the presence of IL-12 + IL-18 or
IL-2 + IL-18 for 3 days. Cells harvested at this time point
were again exclusively NK1.1-CD3- in the
IL-12 + IL-18 group, and
50%
NK1.1+CD3- in the IL-2 + IL-18 group.
These two groups of cells were restimulated with each combination of
cytokines for an additional 3 days, resulting in four subgroups. When
the IL-12 + IL-18 group of cells was again cultured in the same
combination of cytokines, cells remained NK1.1-, and
likewise, stimulating the IL-2 + IL-18 group of cells with
IL-2 + IL-18 increased the proportion of NK1.1+ cells.
In contrast, cultures of these two groups of cells in the presence of
the alternative combination of cytokines resulted in the generation of
populations that reversed back to the original phenotype in terms of
NK1.1 positivity. These results suggest that
NK1.1+CD3- and
NK1.1-CD3- populations are cells of the same
lineage, and their expression of the NK1.1 marker is reversible
depending on the type of cytokine combined with IL-18.
|
|
The NK1.1+CD3- cells present in a
freshly prepared splenic population failed to proliferate in response
to any single type of cytokine. We examined whether the blasts induced
by IL-12 + IL-18 or IL-2 + IL-18 can proliferate by
stimulation with cytokines, especially with a single cytokine. Both
types of blasts were prepared 3 or 4 days after stimulation of a
CD4-CD8-sIg-Ia-
population and restimulated with various cytokines. The results of
Figure 7
show that both types of blasts
respond to either IL-12 + IL-18 or IL-2 + IL-18 stimulation.
Regarding stimulation with a single cytokine, IL-2 induced both types
of blasts to proliferate, but IL-12 did not. IL-18 alone exhibits
significant levels of growth-promoting effects, especially on
IL-12 + IL-18 blasts.
|

Portions of the same blasts generated in Figure 7
were
restimulated with various cytokines for 13 days and culture SNs were
assayed for IFN-
concentrations. The results are shown in Figure 8
. Both IL-12 + IL-18 and IL-2
+ IL-18 blasts produced enormously large amounts of IFN-
exclusively
when they were restimulated with IL-12 + IL-18. Although
IL-12 + IL-18 blasts restimulated with IL-2 + IL-18 exhibited
appreciably higher levels of IFN-
production than groups stimulated
with either cytokine alone, these levels were markedly low compared
with those observed for both types of blasts restimulated with
IL-12 + IL-18. Because either IL-12 or IL-18 alone induced
marginal levels of IFN-
production, these two cytokines can induce
strikingly high levels of IFN-
production only through their
collaboration. We also investigated whether other cytokines such as
IL-1
or IL-1ß in combination with IL-2 or IL-12 can induce IFN-
secretion from IL-12 + IL-18- or IL-2 + IL-18 blasts.
However, such combined stimulation induced only weak (<100 U/ml)
IFN-
secretion compared with the IL-12 + IL-18 stimulation
(data not shown).
|
production, we examined IFN-
production during primary
stimulation of NK1.1+CD3- cells with
IL-12 + IL-18 or IL-2 + IL-18. Figure 9
production even
during primary culture. Stimulation with IL-2 + IL-18 also induced
appreciable levels of IFN-
production on day 4, which may be
consistent with the fact that this combination of cytokines had the
capacity to stimulate IL-12 + IL-18-induced blasts for IFN-
production (Fig. 8
production induced
by IL-2 + IL-18 in both primary (Fig. 9
production by NK cells.
|
We finally examined the cytotoxic activity of IL-12 + IL-18
and IL-2 + IL-18 blasts. Blasts generated 4 days after stimulation
of
CD4-CD8-sIg-Ia-
cells with either IL-12 + IL-18 or IL-2 + IL-18 were assayed
for their cytolytic activity against various tumor target cells (Fig. 10
). Both types of blasts exhibited different degrees
of cytotoxicity depending on the target cell types. However, there was
no substantial difference in the cytolytic activity between two types
of blasts. This was also the case when the cytotoxicity was compared
between Fas-transfected and wild-type targets.
|
| Discussion |
|---|
|
|
|---|
after restimulation with IL-12 + IL-18. The results also
show that while IL-12 + IL-18- and IL-2 + IL-18-blasts derive
from a
NK1.1+CD3-CD4-CD8-
population, the former type of blast lacks the NK1.1 marker. However,
the expression of the NK1.1 marker on the two types of blasts is
reversible depending on whether they are restimulated with IL-12 or
IL-2, together with IL-18. Thus, our present results provide several
new findings and/or important implications, most of which are based on
the roles of IL-18.
Regarding the proliferation of NK cells
(CD3-NK1.1+), IL-2 has been proposed to be the
principal growth factor. Although IL-2 by itself can stimulate NK cell
proliferation (6, 8), IL-2 responsiveness of freshly isolated human NK
cells varies greatly depending on the NK cell subset divided by the
CD56 expression. Whereas CD56bright NK cells, a minor
population of peripheral blood NK cells, respond potently to IL-2, IL-2
alone induces little proliferation for the CD56dull subset
comprising
90% of human NK cells (27, 28, 29). Consistent with
this, freshly isolated CD3-NK1.1+ cells in the
mouse proliferate poorly in response to IL-2 alone (30). Thus,
costimulatory signals have been shown to be required for optimal
proliferation of human (CD56dull) and mouse
(CD3-NK1.1+) NK cells, including a
CD28-mediated signal (30) and soluble factors such as IL-1 and TNF
(31). Nevertheless, the levels of NK cell proliferation enhanced by
such costimulatory signals were not high. In fact, we failed to
obtain sufficient numbers of blasts for analyses when a
CD4-CD8-sIg-Ia-
population as a source of CD3-NK1.1+ cells was
stimulated with IL-2 + IL-1
or ß instead of IL-2 +
IL-18. Moreover, vigorous proliferation of
NK1.1+CD3- cells induced by IL-12 + IL-18
was not prevented by anti-IL-2 mAb (our unpublished observations),
excluding the possibility that endogenous IL-2 is induced by IL-12
+ IL-18 stimulation to act as the major growth factor. Thus, by showing
that high levels of NK1.1+CD3- cell
proliferation are induced by the IL-18-based cytokine combinations, the
present study provides the first evidence for an obligatory role of
IL-18 in the proliferation of NK1.1+CD3-
cells.
In the mouse, NK cells of appropriate strains has been identified as
CD3-NK1.1+ (32). Two sets of the IL-18-based
cytokine combinations (IL-12 + IL-18 and IL-2 + IL-18)
induced the proliferation of this subset present in spleens.
Interestingly, NK cells once activated with IL-12 + IL-18 lost the
NK1.1 marker, whereas most of IL-2 + IL-18-activated NK cells
still expressed the NK1.1 marker. However, the expression of NK1.1 was
reversed when blasts activated with these two cytokine combinations are
restimulated with the alternative combination of cytokines. Both types
of activated NK cells exhibited almost the same levels of functions
including cytotoxicity and IFN-
production. Therefore, it appears
that the expression of the NK1.1 marker correlates neither with the
differentiation/activation stages of NK cells nor with the expression
of its function.
The most prominent function of NK cells stimulated with the IL-18-based
cytokine combinations would be to produce enormous amounts of IFN-
during the primary or secondary stimulation with IL-12 + IL-18.
Previously, it was shown that IL-2 stimulates IFN-
production by T
and NK cells (5, 6, 33). However, in the last several years, IL-12 has
been found to dramatically promote IFN-
secretion from both mouse
and human NK cells (10, 11, 12, 13). IL-12 by itself induces IFN-
secretion
and can also act in synergy with IL-2 and TNF-
(34). While IL-12 has
been regarded as the strongest inducer of IFN-
secretion, another
potent inducer designated IL-18 was more recently discovered (18).
Thus, two powerful reagents capable of stimulating IFN-
production
had still to be investigated for their collaborative actions.
Unlike the up-regulating effect on cytotoxicity, the effect of IL-12 on
IFN-
induction requires the presence of accessory cells (13). This
may be compatible with the observations that IL-1ß is required for
IL-12 to induce IFN-
production by human (35) and mouse (17) NK
cells. Thus, like the induction of NK cell proliferation, costimulatory
signals derived from accessory cells are necessary for IFN-
production by NK cells. In this context, it should be noted that IL-12
induced a dramatically high level of IFN-
secretion in combination
with IL-18 that is derived from a macrophage lineage of cells such as
Kupffer cells (18). Because a combination of IL-12 + IL-1ß
induced much lower levels of IFN-
secretion by NK cells compared
with the combination of IL-12 + IL-18, the latter would represent
the strongest cytokine combination for stimulating IFN-
secretion.
Our ELISA systems using recombinant IFN-
as the standard preparation
have detected surprisingly high levels of IFN-
production by NK
cells following stimulation with IL-12 + IL-18. The possibility
exists that the titers detected may be inflated in the present assays.
Nevertheless, the comparison of the present results with the following
observations supports the distinguished capacity of NK cells to produce
IFN-
. In our preceding paper (36), we measured the titers of IFN-
produced by T cells using the same ELISA systems as those used here. We
found that T cells activated with anti-CD3 plus anti-CD28 mAbs
produce 50 to 100 U/ml of IFN-
in response to IL-12 and IL-18.
Therefore, it is obvious that the levels of IFN-
produced by NK
cells in response to IL-12 + IL-18 are extraordinarily high
compared with those produced by T cells.
Synergy between IL-12 and IL-18 for enhanced production of IFN-
was
shown for a cloned T cell line, 2D6, in our previous study (19). The
results demonstrated that 1) the 2D6 T cell clone constitutively
expressed IL-12R; 2) IL-12 induces the expression of IL-18R on the T
cell clone; and 3) enhanced IFN-
production is elicited when the
IL-18R-induced 2D6 clone is stimulated with IL-18. Because IFN-
secretion by this clone induced following stimulation with IL-12 alone
was much weaker than that with IL-12 + IL-18 (19), the induction
of IL-18R by IL-12 was considered to represent a mechanism underlying
the synergy between IL-12 and IL-18 in enhanced IFN-
production. Our
previous study further investigated whether this synergy is also
observed for naive T cells (19). In contrast to the 2D6 clone, naive T
cells express neither IL-12R nor IL-18R. Therefore, freshly isolated
naive T cells fail to respond to IL-12 and/or IL-18. However,
stimulation of purified T cells with anti-CD3 plus anti-CD28
mAb induced IL-12R expression, and these activated T cells were
stimulated with IL-12 and IL-18 to exhibit the above mechanism of
synergy for enhanced IFN-
secretion.
In the present study, NK1.1+CD3- cells could
proliferate in response to the combination of IL-12 + IL-18 or
IL-2 + IL-18. However, strikingly high levels of IFN-
secretion
was induced only when freshly prepared
NK1.1+CD3- cells or blasts activated with
either of the two cytokine-combinations were stimulated with IL-12
+ IL-18. The fact that NK1.1+CD3- cells can
respond to IL-12 + IL-18 without activation with any stimulus such
as anti-CD3 differs from the failure of naive resting T cells to
respond to these cytokines. Neither IL-12R nor IL-18R was detected on
preactivated and activated NK cells in our previously described assay
system (19) using ligands (IL-12 and IL-18) and anti-ligand Abs
(our unpublished observations). While fresh NK1.1+
CD3- cells failed to show IL-18 responsiveness, day 4
blasts obtained after stimulation with IL-12 + IL-18 exhibited the
proliferative response to IL-18 alone. Although these results suggest
that the expression of IL-18R is up-regulated on the activated (blast)
NK population, IL-18R was not detected even on such a blast population
(our unpublished observations). Regarding IL-12R expression, it is
possible that at least IL-12R is expressed on freshly isolated
NK1.1+CD3- cells as has been described for
resting human NK cells (37). By combining this possibility with the
fact that IL-12 has the capacity to induce the expression of IL-18R on
T cells (19), it may be assumed that IL-12 first induces
NK1.1+CD3- cells to express IL-18R and then
these cells can respond vigorously to the combined stimulation of
IL-12 + IL-18. This is consistent with the concept that IL-12
+ IL-18 is the most potent cytokine combination for IFN-
production.
Our present results illustrate that IL-18 exerts its striking effects on the proliferation and activation of NK1.1+CD3- cells when combined with another proinflammatory cytokine, IL-12. Considering that significant numbers of NK1.1+CD3- cells reside in the liver and IL-18 is produced efficiently by Kupffer cells, NK cell activation induced by IL-12 + IL-18 may represent a molecular mechanism underlying the development of inflammatory responses in the liver. It may also be possible to control various diseases by regulating the collaborative action of IL-12 and IL-18.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Hiromi Fujiwara, Biomedical Research Center, Osaka University Medical School, 2-2, Yamada-oka, Suita, Osaka 565, Japan. ![]()
3 Abbreviations used in this paper: SN, supernatant; PE, phycoerythrin; sIg, surface Ig; DN, double negative. ![]()
Received for publication October 3, 1997. Accepted for publication January 14, 1998.
| References |
|---|
|
|
|---|
. J. Immunol. 139:1104.[Abstract]
that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J. Exp. Med. 178:567.
ß+, TCR-
+ T lymphocytes, and NK cells. J. Immunol. 149:3495.[Abstract]
by NK cells: a role for IL-1 ß in the T cell-independent mechanism of resistance against intracellular pathogens. J. Immunol. 155:4347.[Abstract]
production by T cells. Nature 378:88.[Medline]
-inducing factor in enhanced production of IFN-
. J. Immunol 159:2125.
-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently IL-12. J. Immunol. 158:1541.[Abstract]
-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur. J. Immunol. 26:1647.[Medline]
by resting human T cells and large granular lymphocytes: requirement for accessory cell factors, including interleukin-1. Cell. Immunol. 113:130.[Medline]
are costimulators of interferon
production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc. Natl. Acad. Sci. USA 90:3725.
-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. 178:1041.
in response to IL-18. J. Immunol. 160:3759.This article has been cited by other articles:
![]() |
S. J. Park, M. A. Hughes, M. Burdick, R. M. Strieter, and B. Mehrad Early NK Cell-Derived IFN-{gamma} Is Essential to Host Defense in Neutropenic Invasive Aspergillosis J. Immunol., April 1, 2009; 182(7): 4306 - 4312. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. I. Chaudhry, T. P. Kingham, G. Plitas, S. C. Katz, J. R. Raab, and R. P. DeMatteo Combined Stimulation with Interleukin-18 and CpG Induces Murine Natural Killer Dendritic Cells to Produce IFN-{gamma} and Inhibit Tumor Growth Cancer Res., November 1, 2006; 66(21): 10497 - 10504. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Maxwell, R. Yadav, R. J. Rossi, C. E. Ruby, A. D. Weinberg, H. L. Aguila, and A. T. Vella IL-18 Bridges Innate and Adaptive Immunity through IFN-{gamma} and the CD134 Pathway J. Immunol., July 1, 2006; 177(1): 234 - 245. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Svensson, J. Kaim, C. Mallard, A. Olsson, E. Brodin, T. Hokfelt, and K. Eriksson Neurokinin 1 Receptor Signaling Affects the Local Innate Immune Defense against Genital Herpes Virus Infection J. Immunol., November 15, 2005; 175(10): 6802 - 6811. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Svensson, I. Nordstrom, J.-B. Sun, and K. Eriksson Protective Immunity to Genital Herpes Simpex Virus Type 2 Infection Is Mediated by T-bet J. Immunol., May 15, 2005; 174(10): 6266 - 6273. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Tenger, A. Sundborger, J. Jawien, and X. Zhou IL-18 Accelerates Atherosclerosis Accompanied by Elevation of IFN-{gamma} and CXCL16 Expression Independently of T Cells Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 791 - 796. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Rosenthal, L. D. Mikus, A. Tuffaha, A. G. Mosser, R. L. Sorkness, and R. F. Lemanske Jr. Attenuated Innate Mechanisms of Interferon-{gamma} Production in Rats Susceptible to Postviral Airway Dysfunction Am. J. Respir. Cell Mol. Biol., May 1, 2004; 30(5): 702 - 709. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Bossu, D. Neumann, E. Del Giudice, A. Ciaramella, I. Gloaguen, G. Fantuzzi, C. A. Dinarello, E. Di Carlo, P. Musiani, P. L. Meroni, et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease PNAS, November 25, 2003; 100(24): 14181 - 14186. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. W. Gobel, K. Schneider, B. Schaerer, I. Mejri, F. Puehler, S. Weigend, P. Staeheli, and B. Kaspers IL-18 Stimulates the Proliferation and IFN-{gamma} Release of CD4+ T Cells in the Chicken: Conservation of a Th1-Like System in a Nonmammalian Species J. Immunol., August 15, 2003; 171(4): 1809 - 1815. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhao, H. Ohdan, J. O. Manilay, and M. Sykes NK Cell Tolerance in Mixed Allogeneic Chimeras J. Immunol., June 1, 2003; 170(11): 5398 - 5405. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ito, A. Matejuk, C. Hopke, H. Drought, J. Dwyer, A. Zamora, S. Subramanian, A. A. Vandenbark, and H. Offner Transfer of Severe Experimental Autoimmune Encephalomyelitis by IL-12- and IL-18-Potentiated T Cells Is Estrogen Sensitive J. Immunol., May 1, 2003; 170(9): 4802 - 4809. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Minagawa, H. Watanabe, C. Miyaji, K. Tomiyama, H. Shimura, A. Ito, M. Ito, J. Domen, I. L. Weissman, and K. Kawai Enforced Expression of Bcl-2 Restores the Number of NK Cells, But Does Not Rescue the Impaired Development of NKT Cells or Intraepithelial Lymphocytes, in IL-2/IL-15 Receptor {beta}-Chain-Deficient Mice J. Immunol., October 15, 2002; 169(8): 4153 - 4160. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nakahira, H.-J. Ahn, W.-R. Park, P. Gao, M. Tomura, C.-S. Park, T. Hamaoka, T. Ohta, M. Kurimoto, and H. Fujiwara Synergy of IL-12 and IL-18 for IFN-{gamma} Gene Expression: IL-12-Induced STAT4 Contributes to IFN-{gamma} Promoter Activation by Up-Regulating the Binding Activity of IL-18-Induced Activator Protein 1 J. Immunol., February 1, 2002; 168(3): 1146 - 1153. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Jordan, R.-F. Guo, E. C. Yun, V. Sarma, R. L. Warner, L. D. Crouch, G. Senaldi, T. R. Ulich, and P. A. Ward Role of IL-18 in Acute Lung Inflammation J. Immunol., December 15, 2001; 167(12): 7060 - 7068. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Borges, A. Campos-Neto, P. Sleath, K. H. Grabstein, P. J. Morrissey, Y. A. W. Skeiky, and S. G. Reed Potent Stimulation of the Innate Immune System by a Leishmania brasiliensis Recombinant Protein Infect. Immun., September 1, 2001; 69(9): 5270 - 5277. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Harandi, B. Svennerholm, J. Holmgren, and K. Eriksson Interleukin-12 (IL-12) and IL-18 Are Important in Innate Defense against Genital Herpes Simplex Virus Type 2 Infection in Mice but Are Not Required for the Development of Acquired Gamma Interferon-Mediated Protective Immunity J. Virol., July 15, 2001; 75(14): 6705 - 6709. [Abstract] [Full Text] |
||||
![]() |
D. Neumann, E. Del Giudice, A. Ciaramella, D. Boraschi, and P. Bossu Lymphocytes from Autoimmune MRL lpr/lpr Mice Are Hyperresponsive to IL-18 and Overexpress the IL-18 Receptor Accessory Chain J. Immunol., March 15, 2001; 166(6): 3757 - 3762. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. D. Mikus, L. A. Rosenthal, R. L. Sorkness, and R. F. Lemanske Jr. Reduced Interferon-{gamma} Secretion by Natural Killer Cells from Rats Susceptible to Postviral Chronic Airway Dysfunction Am. J. Respir. Cell Mol. Biol., January 1, 2001; 24(1): 74 - 82. [Abstract] [Full Text] |
||||
![]() |
B. R. Lauwerys, N. Garot, J.-C. Renauld, and F. A. Houssiau Cytokine Production and Killer Activity of NK/T-NK Cells Derived with IL-2, IL-15, or the Combination of IL-12 and IL-18 J. Immunol., August 15, 2000; 165(4): 1847 - 1853. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. E. Carson, J. E. Dierksheide, S. Jabbour, M. Anghelina, P. Bouchard, G. Ku, H. Yu, H. Baumann, M. H. Shah, M. A. Cooper, et al. Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-gamma production and STAT-mediated signal transduction Blood, August 15, 2000; 96(4): 1465 - 1473. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ishihara, M. Nieda, J. Kitayama, T. Osada, T. Yabe, A. Kikuchi, Y. Koezuka, S. A. Porcelli, K. Tadokoro, H. Nagawa, et al. {alpha}-Glycosylceramides Enhance the Antitumor Cytotoxicity of Hepatic Lymphocytes Obtained from Cancer Patients by Activating CD3-CD56+ NK Cells In Vitro J. Immunol., August 1, 2000; 165(3): 1659 - 1664. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Fehniger, H. Yu, M. A. Cooper, K. Suzuki, M. H. Shah, and M. A. Caligiuri Cutting Edge: IL-15 Costimulates the Generalized Shwartzman Reaction and Innate Immune IFN-{gamma} Production In Vivo J. Immunol., February 15, 2000; 164(4): 1643 - 1647. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Dybing, N. Walters, and D. W. Pascual Role of Endogenous Interleukin-18 in Resolving Wild-Type and Attenuated Salmonella typhimurium Infections Infect. Immun., December 1, 1999; 67(12): 6242 - 6248. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Caamano, J. Alexander, L. Craig, R. Bravo, and C. A. Hunter The NF-{kappa}B Family Member RelB Is Required for Innate and Adaptive Immunity to Toxoplasma gondii J. Immunol., October 15, 1999; 163(8): 4453 - 4461. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Thomas, J. L. Allen, M. Tsen, T. Dubnicoff, J. Danao, X. C. Liao, Z. Cao, and S. A. Wasserman Impaired Cytokine Signaling in Mice Lacking the IL-1 Receptor-Associated Kinase J. Immunol., July 15, 1999; 163(2): 978 - 984. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Walker, M. Aste-Amezaga, R. A. Kastelein, G. Trinchieri, and C. A. Hunter IL-18 and CD28 Use Distinct Molecular Mechanisms to Enhance NK Cell Production of IL-12-Induced IFN-{gamma} J. Immunol., May 15, 1999; 162(10): 5894 - 5901. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Fehniger, M. H. Shah, M. J. Turner, J. B. VanDeusen, S. P. Whitman, M. A. Cooper, K. Suzuki, M. Wechser, F. Goodsaid, and M. A. Caligiuri Differential Cytokine and Chemokine Gene Expression by Human NK Cells Following Activation with IL-18 or IL-15 in Combination with IL-12: Implications for the Innate Immune Response J. Immunol., April 15, 1999; 162(8): 4511 - 4520. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |